Why GLP-1s aren't lowering employers' costs

Despite the promise of long-term health savings, employer-sponsored GLP-1 weight-loss drugs are not reducing healthcare costs for most companies — and here’s why. The story of Nick Miller, a Connecticut state employee who lost over 150 pounds on Ozempic with full employer coverage, illustrates the life-changing benefits of these medications. Yet even as his health improved dramatically, his employer’s spending on the program rose, not fell. According to health economist Chris Whaley, the assumption that better health automatically means lower costs is flawed. The drugs themselves are extremely expensive — up to $1,700 a month — and employers often pay for them through higher premiums or reduced wages. Additional costs come from the management programs required to qualify for coverage, which many employers outsource. Crucially, health improvements take years to materialize, by which time employees are often no longer covered by the same plan — and healthier people still use healthcare, whether for pickleball injuries or other issues. The real savings come not from better health, but from restricting access: limiting who gets the drug in the first place. While the moral and personal value of these treatments is undeniable, the financial math for employers remains unconvincing — at least for now.